Cost-effectiveness of TNF-Α-blocking agents in the treatment of rheumatoid arthritis

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 9, 2004, Pages 1881-1886

  Merkesdal, Sonja ^a   Ruof, Jörg ^a   Mittendorf, Thomas ^b   Zeidler, Henning ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

Biological treatment; Cost effectiveness; Cost utility analysis; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA ANALYSIS; DRUG COST; DRUG RESPONSE; HUMAN; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOGLOBULIN G; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4544224577     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.9.1881     Document Type: Review

References (20)

1. MERKESDAL S, RUOF J, MITTENDORF T, MAU W, ZEIDLER H: [Health economic research in rheumatoid arthritis]. Z. Rheumatol. (2002) 61:21-29.
2. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. (1999) 6:478-487.
3. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: Trial of etanercept, a recombinant tumor necrosis factor receptor-Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. (1999) 4:253-259.
4. LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. (2000) 22:1594-1602.
5. KAVANAUGH A, ST CLAIR EW, MCCUNE WJ, BRAAKMAN T, LIPSKY P: Chimeric anti-rumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J. Rheumatol. (2000) 27:841-850.
6. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet (1999) 354:1932-1939.
7. Cost-effectiveness in health and medicine. Gold MR, Siegel JE, Russel LB, Weinstein M (Eds), Oxford University Press, Inc., Oxford, New York, USA (1996).
8. CHOI HK, SEEGER JD, KUNTZ KM: A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum. (2000) 43:2316-2327.
9. CHOI HK, SEEGER JD, KUNTZ KM: A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J. Rheumatol. (2002) 29:1156-1165.
10. KOBELT G, JONSSON L, YOUNG A, EBERHARDT K: The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (2003) 42:326-335.
11. WONG JB, SINGH G, KAVANAUGH A: Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am. J. Med. (2002) 113:400-408.
12. BRENNAN A, BANSBACK N, REYNOLDS A, CONWAY P: Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK Rheumatology (2004) 43:62-72.
13. KOBELT G, EBERHARDT K, GEBOREK P: TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann. Rheum. Dis. (2004) 63:4-10.
14. JOBANPUTRA P, BARTON P, BRYAN S, BURLS A: The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess. (2002) 6:1-110.
15. NUIJTEN MJ, ENGELFRIET P, DUIJN K, BRUIJN G, WIERZ D, KOOPMANSCHAP M: A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics (2001) 19:1051-1064.
16. HARLEY CR, FRYTAK JR, TANDON N: Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am. J. Manag. Care (2003) 9(6 Suppl.): 136-143.
17. GABRIEL S, DRUMMOND M, MAETZEL A et al.: OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J. Rheumatol. (2003) 30:886-890.
18. BINGHAM SJ, BUCH MH, TENNANT A, EMERY P: The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy. Rheumatology (2004) 43:364-368.
19. KULP W, CORZELLIUS M, GREINER W et al.: [Value of TNF-alpha blocking agents in RA-Therapy]. German Institute of Medical Documentation and Information (2004).
20. FURST DE, BREEDVELD FC, KALDEN JR et al.: Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann. Rheum. Dis. (2003) 62(Suppl. II):ii2-ii9.